EP4090658A4 - THERAPEUTIC MEDICATIONS AND TREATMENT METHODS - Google Patents

THERAPEUTIC MEDICATIONS AND TREATMENT METHODS Download PDF

Info

Publication number
EP4090658A4
EP4090658A4 EP21741940.7A EP21741940A EP4090658A4 EP 4090658 A4 EP4090658 A4 EP 4090658A4 EP 21741940 A EP21741940 A EP 21741940A EP 4090658 A4 EP4090658 A4 EP 4090658A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21741940.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4090658A1 (en
Inventor
Guangrong Zheng
Daohong Zhou
Xuan Zhang
Wanyi HU
Xingui LIU
Dongwen LYU
Yaxia YUAN
Dinesh Thummuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of EP4090658A1 publication Critical patent/EP4090658A1/en
Publication of EP4090658A4 publication Critical patent/EP4090658A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21741940.7A 2020-01-15 2021-01-15 THERAPEUTIC MEDICATIONS AND TREATMENT METHODS Pending EP4090658A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961330P 2020-01-15 2020-01-15
PCT/US2021/013602 WO2021146536A1 (en) 2020-01-15 2021-01-15 Therapeutic agents and methods of treatment

Publications (2)

Publication Number Publication Date
EP4090658A1 EP4090658A1 (en) 2022-11-23
EP4090658A4 true EP4090658A4 (en) 2024-03-13

Family

ID=76864811

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21741940.7A Pending EP4090658A4 (en) 2020-01-15 2021-01-15 THERAPEUTIC MEDICATIONS AND TREATMENT METHODS

Country Status (8)

Country Link
US (1) US20230339929A1 (ja)
EP (1) EP4090658A4 (ja)
JP (1) JP2023510885A (ja)
KR (1) KR20220129589A (ja)
CN (1) CN115038697A (ja)
AU (1) AU2021207672A1 (ja)
CA (1) CA3163593A1 (ja)
WO (1) WO2021146536A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215449A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
US20240238423A9 (en) 2022-05-06 2024-07-18 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215471A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023246924A1 (zh) * 2022-06-24 2023-12-28 南京瑞初医药有限公司 苯并噻唑化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094509A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
EP3455219A4 (en) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2018092064A1 (en) * 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
CA3163593A1 (en) 2021-07-22
CN115038697A (zh) 2022-09-09
WO2021146536A8 (en) 2021-08-26
EP4090658A1 (en) 2022-11-23
JP2023510885A (ja) 2023-03-15
AU2021207672A1 (en) 2022-07-14
US20230339929A1 (en) 2023-10-26
WO2021146536A1 (en) 2021-07-22
KR20220129589A (ko) 2022-09-23

Similar Documents

Publication Publication Date Title
EP3920923A4 (en) THERAPEUTICS AND TREATMENT METHODS
EP4090658A4 (en) THERAPEUTIC MEDICATIONS AND TREATMENT METHODS
IL299167A (en) Compositions and methods for treating patients with gene therapy
EP4058037A4 (en) FIBROBLAST THERAPY FOR THE TREATMENT AND PREVENTION OF STROKE
EP4110369A4 (en) TREATMENT METHODS AND RELATED COMPOSITIONS
EP4173446A4 (en) DEVICES AND METHODS FOR TREATING SKIN TISSUE WITH COLD PLASMA
EP4017493A4 (en) TREATMENT METHODS USING BCN057 AND BCN512
IL309317A (en) Treatment of diseases and disorders associated with MTRES1
AU2021381324A9 (en) Methods of treating diseases and disorders
EP4248212A4 (en) METHODS OF TREATING DISEASES AND DISORDERS
EP4138852A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
EP4106731A4 (en) THERAPEUTIC NANOPARTICLES AND MANUFACTURING METHODS
EP4238567A4 (en) NOVEL TREATMENT AND PREVENTION OF SARCOPENIA-RELATED DISEASES
EP4076527A4 (en) COMBINATION DRUG THERAPIES AND THEIR METHODS OF USE
EP4099997A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP4135644A4 (en) DIAGNOSTIC AND THERAPEUTIC SPLINTS AND METHODS OF USE
EP4118210A4 (en) TREATMENT OF COVID-19 AND METHODS THEREFOR
AU2020901854A0 (en) Therapeutic methods and agents
AU2020901800A0 (en) Therapeutic methods and agents
AU2021902069A0 (en) Methods of treatment and inhibition
EP4121166C0 (en) THERAPEUTIC TREATMENT OF CHROMATINOPATHIES
EP4090420A4 (en) PHOTOTHERAPEUTIC TREATMENT OF SKIN DISEASES
AU2020902697A0 (en) Massage therapy devices and techniques
GB202105874D0 (en) COVID-19 Therapeutic antennapedia-antibody molecules and methods of use thereof
GB202002030D0 (en) Treatment and prevention of metabolic diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082003

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0401140000

Ipc: C07D0417140000

A4 Supplementary search report drawn up and despatched

Effective date: 20240214

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/428 20060101ALI20240208BHEP

Ipc: A61P 35/00 20060101ALI20240208BHEP

Ipc: C07D 417/14 20060101AFI20240208BHEP